Emergence of an Extensive Drug Resistant Citrobacter portucalensis Clinical Strain Harboring blaSFO-1, blaKPC-2, and blaNDM-1
DOI: https://doi.org/10.2147/idr.s461118
2024-06-04
Infection and Drug Resistance
Abstract:Kexin Guo, 1, &ast Zanzan Zhao, 1, &ast Yu Yang, 1 Xiawei Jiang, 1 Hao Xu, 2 Fangfang Tao, 1 Ye Xu, 1 Wenhong Liu 1 1 School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China; 2 Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wenhong Liu, School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, People's Republic of China, Email Background: To explore the plasmid characteristics and transfer mechanisms of an extensive drug resistant (XDR) clinical isolate, Citrobacter portucalensis L2724hy, co-producing bla SFO-1 , bla NDM-1 , and bla KPC-2 . Methods: Species confirmation of L2724hy was achieved through 16S rRNA sequencing and Average Nucleotide Identity (ANI) analysis. Antimicrobial susceptibility testing (AST) employed the agar dilution and micro broth dilution methods. Identification of resistance genes was carried out by PCR and whole-genome sequencing (WGS). Essential resistance gene locations were verified by S1 nuclease pulsed-field gel electrophoresis (S1-PFGE) and southern hybridization experiments. Subsequent WGS data analysis delved into drug resistance genes and plasmids. Results: The confirmation of the strain L2724hy as an extensive drug-resistant Citrobacter portucalensis, resistant to almost all antibiotics tested except polymyxin B and tigecycline, was achieved through 16S rRNA sequencing, ANI analysis and AST results. WGS and subsequent analysis revealed L2724hy carrying bla SFO-1 , bla NDM-1 , and bla KPC-2 on plasmids of various sizes. The uncommon ESBL gene bla SFO-1 coexists with the fosA3 gene on an IncFII plasmid, featuring the genetic environment IS 26-fosA3 -IS 26-ampR-bla SFO-1 -IS 26 . The bla NDM-1 was found on an IncX3 plasmid, coexisting with bla SHV-12 , displaying the sequence IS 5 -IS 3000 -IS 3000 -Tn 2-bla NDM-1 - ble-trpF-dsbD-cutA-gros-groL , lacking IS Aa125 . The bla KPC-2 is located on an unclassified plasmid, exhibiting the sequence Tn 2-tnpR -IS Kpn27-bla KPC-2 -IS Kpn6-korC . Conjugation assays confirmed the transferability of both bla NDM-1 and bla KPC-2 . Conclusion: We discovered the coexistence of bla SFO-1 , bla NDM-1 , and bla KPC-2 in C. portucalensis for the first time, delving into plasmid characteristics and transfer mechanisms. Our finding highlights the importance of vigilant monitoring of drug-resistance genes and insertion elements in uncommon strains. Keywords: Citrobacter spp , XDR, bla SFO , bla NDM , bla KPC , IncFII In the vast microbial landscape, the genus Citrobacter stands as a diverse group of bacteria known for its adaptability and ecological ubiquity. Within this genus, the relatively lesser-explored C. portucalensis has garnered attention for its potential contributions to various fields, especially in human health. Since its first report in 2017, diverse occurrences of C. portucalensis in wastewater, sputum, stool, sludge, poultry and, sea turtles across multiple countries have been discovered. 1–6 In 2021, Chinese researcher Cao et al isolated C. portucalensis carrying bla NDM-1 from clinical specimens for the first time. 2 Subsequently, in 2022, the coexistence of bla KPC-2 and bla NDM-1 was reported in an extensively drug-resistant C. portucalensis obtained from a hospital in China. 7 Additionally, in 2023, researchers isolated C. portucalensis carrying bla NDM-1 from an endangered marine animal that died from sepsis. 8 This growing body of evidence underscores the increasing clinical and extra-clinical dissemination of drug-resistant C. portucalensis , warranting heightened attention to address the associated public health concerns. In 2017, the World Health Organization (WHO) designat -Abstract Truncated-
pharmacology & pharmacy,infectious diseases